exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088741 RNA Name: hsa-miR-4709-5p RNA Type: miRNA Chromosome: chr14 Starnd: - Coordinate: Start Site(bp): 74480175 End Site(bp): 74480196 External Links: hsa-miR-4709-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BCORL1 chrX 129981107 130058083 + CBX2 chr17 79778148 79787983 + CTNND1 chr11 57753243 57819546 + DNAJB6 chr7 157335381 157417439 + ERP29 chr12 112013348 112023449 + LAMC1 chr1 183023420 183145592 + ARID4B chr1 235131634 235328219 - CLSTN3 chr12 7129698 7158945 + DHX16 chr6 30653119 30673006 - GFM2 chr5 74721206 74767147 - HNRNPL chr19 38836388 38852347 - HOXB13 chr17 48724763 48729178 - HSP90AA1 chr14 102080738 102139699 - IDH1 chr2 208236227 208266074 - IREB2 chr15 78437431 78501453 + MKKS chr20 10401009 10434222 - MSH3 chr5 80654652 80876815 + NPC2 chr14 74476192 74494177 - PABPC1 chr8 100685816 100722809 - PODXL chr7 131500262 131558217 - PRDX5 chr11 64318121 64321811 + SCAF8 chr6 154733325 154834244 + TIAM2 chr6 154832697 155257723 + UGP2 chr2 63840940 63891562 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005479.1 chr14 74474007 74474864 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.